Novo Nordisk’s multibillion-dollar honeymoon phase spearheaded by Ozempic and Wegovy is ending. Now the Danish drugmaker is ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

Novo Nordisk boasts 45 million customers using its drug, which has caused a revolution in weight-loss treatment. But competitors are nipping at its heels.

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other perks.

Eli Lilly's corresponding weight-loss drugs to Novo Nordisk's obesity drug Wegovy and diabetes treatment Ozempic are Zepbound and Mounjaro, positioning the firm as a major rival to the Danish ...

Telehealth company Hims Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face ...

claim the company misrepresented the likelihood of CagriSema achieving at least 25% weight loss in the study. The suit alleges that Novo Nordisk created a "false impression" of reliable data ...

Telehealth provider Hims & Hers Health is defending its planned Super Bowl ad, which is styled as a political manifesto ...

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Recently, Novo Nordisk revealed trial results for two new obesity drugs, CagriSema and Amycretin. The former disappointed investors with less-than-projected weight loss, resulting in ... are now ...